Drugs / SU014813
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00982267 | Dec 2003 → Nov 2008 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00322517 | Apr 2006 → Jun 2008 | breast neoplasm | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SU014813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00982267 ↗ |
| Action | Inhibit | “an oral multitargeted tyrosine kinase inhibitor” PMID 20605934 ↗ Jul 20102“Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1721885 ↗ “Stem cell growth factor receptor inhibitor” CHEMBL1721885 ↗ |
| Modality | Small molecule | “an oral multitargeted tyrosine kinase inhibitor” PMID 20605934 ↗ Jul 2010 |
| Route | Oral | “100 mg orally once daily” NCT00322517 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1721885 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL1721885 ↗ |